Systemic lupus erythematosus: history and modernity
https://doi.org/10.47360/1995-4484-2022-397-412
Abstract
Systemic lupus erythematosus (SLE) is a systemic autoimmune rheumatic disease of unknown etiology, characterized by hyperproduction of non-organ-specific autoantibodies to various components of the cell nucleus and the development of immune-inflammatory damage to internal organs. Currently, SLE is considered as a prototype of a systemic human autoimmune pathology, the central mechanism of immunopathogenesis of which is a violation of immunological tolerance to self-antigens, due to a complex interaction of genetic, epigenetic, environmental factors. The publication discusses the history of the study of SLE, the contribution of Russian scientists (V.A. Nasonova and others) to the study of th is problem, current trends in clinical and scientific research related to the improvement of diagnostic criteria and pharmacotherapy of this disease.
About the Authors
E. L. Nasonov
V.A. Nasonova Research Institute of Rheumatology V.A. Nasonova Research Institute of Rheumatology;
I.M. Sechenov First Moscow State Medical University of the Ministry of Health Care of Russian Federation (Sechenov University)
Russian Federation
Russian Federation
119991, Moscow, Trubetskaya str., 8, building 2
S. K. Soloviev
V.A. Nasonova Research Institute of Rheumatology V.A. Nasonova Research Institute of Rheumatology
Russian Federation
Russian Federation
A. V. Arshinov
Yaroslavl State Medical University
Russian Federation
Russian Federation
150000, Yaroslavl, Revolyutsionnaya str., 5
References
1. Tsokos GC. Systemic lupus erythematosus. N Engl J Med. 2011; 365(22):2110-2121. doi: 10.1056/NEJMra1100359
2. Kaul A, Gordon C, Crow MK, Touma Z, Urowitz MB, van Vollenhoven R, et al. Systemic lupus erythematosus. Nat Rev Dis Primers. 2016;2:16039. doi: 10.1038/nrdp.2016.39
3. Norman RA. The History of lupus erythematosus and discoid lupus: From Hippocrates to the present. Lupus Open Access. 2016;1(1):102.
4. Kaposi M. Neue Beiträge zur Kenntniss des Lupus erythematosus. Arch Derm Syphilol. 1872;4:36-78.
5. Osler W. On the visceral complications of erythema exudativum multiforme. Am J Med Sci. 1895;110:629-646.
6. Sequeira JH, Balean H. Lupus erythematosus: A clinical study of seventy-one cases. Br J Dermatol. 1902;14:367-379.
7. Libman E, Sachs B. A hitherto undescribed form of valvular and mural endocarditis. Arch Inter Med. 1924;33:701-737.
8. Baehr G, Klemperer P, Chifrin A. Diffuse disease of the peripheral circulation usually associated with lupus erythematosus and endocarditis. Trans Assoc Am Phis. 1935;50:139-155.
9. Hargraves MM, Richmond H, Morton R. Presentation of two bone marrow elements; “tart” cell and “L.E.” cell. Proc Staff Meet Mayo Clin. 1948 Jan 21;23:25-28.
10. Haserick JR, Long R. Systemic lupus erythematosus preceded by false-positive test for syphilis: Presentations five cases. Ann Intern Med. 1952;37:559-565.
11. Nasonova VA. Systemic lupus erythematosus. Moscow:Meditsina; 1972 (In Russ.).
12. Tareev EM, Vinogradova OM, Nasonova VA, Guseva NG. Collagenoses. Moscow;1965 (In Russ.).
13. Page F. Treatment of lupus erythematosus with mepacrine. Lancet. 1951;2:755-758. 14. Wallace DJ. The history of antimalarials. Lupus. 1996;5(Suppl 1): S2-S3.
14. Dima A, Jurcut C, Chasset F, Felten R, Arnaud L. Hydroxychloroquine in systemic lupus erythematosus: Overview of current knowledge. Ther Adv Musculoskelet Dis. 2022;14:1759720X211073001. doi: 10.1177/1759720X211073001
15. Almeida-Brasil CC, Hanly JG, Urowitz M, Clarke AE, RuizIrastorza G, Gordon C, et al. Flares after hydroxychloroquine reduction or discontinuation: Results from the Systemic Lupus International Collaborating Clinics (SLICC) inception cohort. Ann Rheum Dis. 2022;81(3):370-378. doi: 10.1136/annrheumdis-2021-221295
16. Hench PS, Kendall EC. The effect of a hormone of the adrenal cortex (17-hydroxy-11-dehydrocorticosterone; compound E) and of pituitary adrenocorticotropic hormone on rheumatoid arthritis. Proc Staff Meet Mayo Clin. 1949;24:181-197.
17. Hench PS. The reversibility of certain rheumatic and nonrheumatic conditions by the use of cortisone or of the pituitary adrenocotropic hormone. Ann Intern Med. 1952;36:1-38.
18. Ruiz-Irastorza G, Ugarte A, Ruiz-Arruza I, Khamashta M. Seventy years after Hench’s Nobel prize: Revisiting the use of glucocorticoids in systemic lupus erythematosus. Lupus. 2020;29(10):1155- 1167. doi: 10.1177/0961203320930099
19. Cathcart ES, Idelson BA, Scheinberg MA, Couser WG. Beneficial effects of methylprednisolone “pulse” therapy in diffuse proliferative lupus nephritis. Lancet. 1976;i:163-166. 21. Scheinberg M. The history of pulse therapy in lupus nephritis (1976–2016). Lupus Science Medicine. 2016;3:e000149. doi: 10.1136/lupus-2016-000149
20. Porta S, Danza A, Arias Saavedra M, Carlomagno A, Goizueta MC, Vivero F, et al. Glucocorticoids in systemic lupus erythematosus. Ten questions and some issues. J Clin Med. 2020;9(9):2709. doi: 10.3390/jcm9092709
21. Ugarte-Gil MF, Mak A, Leong J, Dharmadhikari B, Kow NY, Reátegui-Sokolova C, et al. Impact of glucocorticoids on the incidence of lupus-related major organ damage: A systematic literature review and meta-regression analysis of longitudinal observational studies. Lupus Sci Med. 2021;8(1):e000590. doi: 10.1136/lupus-2021-000590
22. Osborne ED, Jordon JW, Hoak FC, Pschierer FJ. Nitrogen mustard therapy in cutaneous blastomatous disease. JAMA. 1947;135: 1123-1128.
23. Alekberova ZS, Parfanovich MI, Nasonova VA, Zhdanov VM. Molecular pathogenesis of systemic lupus erythematosus. Arch Virol. 1975;47(2):109-121. doi: 10.1007/BF01320551
24. Iwata S, Tanaka Y. Association of viral infection with the development and pathogenesis of systemic lupus erythematosus. Front Med (Lausanne). 2022;9:849120. doi: 10.3389/fmed.2022.849120
25. Tsokos GC. Autoimmunity and organ damage in systemic lupus erythematosus. Nat Immunol. 2020;21(6):605-614. doi: 10.1038/s41590-020-0677-6
26. Gupta S, Kaplan MJ. Bite of the wolf: innate immune responses propagate autoimmunity in lupus. J Clin Invest. 2021;131(3): e144918. doi: 10.1172/JCI144918
27. Pisetsky DS, Lipsky PE. New insights into the role of antinuclear antibodies in systemic lupus erythematosus. Nat Rev Rheumatol. 2020;16(10):565-579. doi: 10.1038/s41584-020-0480-7
28. Aringer M, Costenbader K, Daikh D, Brinks R, Mosca M, Ramsey-Goldman R, et al. 2019 European League Against Rheumatism/American College of Rheumatology classification criteria for systemic lupus erythematosus. Ann Rheum Dis. 2019;78(9):1151- 1159. doi: 10.1136/annrheumdis-2018-214819
29. Aringer M, Johnson SR. Classifying and diagnosing systemic lupus erythematosus in the 21st century. Rheumatology (Oxford). 2020;59(Suppl 5):v4-v11. doi: 10.1093/rheumatology/keaa379
30. Johnson SR, Brinks R, Costenbader KH, Daikh D, Mosca M, Ramsey-Goldman R, et al. Performance of the 2019 EULAR/ ACR classification criteria for systemic lupus erythematosus in early disease, across sexes and ethnicities. Ann Rheum Dis. 2020;79(10):1333-1339. doi: 10.1136/annrheumdis-2020-217162
31. Leuchten N, Hoyer A, Brinks R, Schoels M, Schneider M, Smolen J, et al.; Systemic Lupus Erythematosus Classification Criteria Steering Committee. Performance of antinuclear antibodies for classifying systemic lupus erythematosus: A systematic literature review and meta-regression of diagnostic data. Arthritis Care Res (Hoboken). 2018;70(3):428-438. doi: 10.1002/acr.23292
32. Pisetsky DS, Bossuyt X, Meroni PL. ANA as an entry criterion for the classification of SLE. Autoimmun Rev. 2019:102400. doi: 10.1016/j.autrev.2019.102400
33. Aringer M, Costenbader K, Dörner T, Johnson SR. Advances in SLE classification criteria. J Autoimmun. 2022:102845. doi: 10.1016/j.jaut.2022.102845
34. Sciascia S, Roccatello D, Radin M, Parodis I, Yazdany J, PonsEstel G, et al. Differentiating between UCTD and early-stage SLE: From definitions to clinical approach. Nat Rev Rheumatol. 2022;18(1):9-21. doi: 10.1038/s41584-021-00710-2
35. Nasonov EL, Popkova TV, Panafidina TA. Problems of early diagnosis of systemic lupus erythematosus during the COVID19 pandemic. Nauchno-Prakticheskaya Revmatologia = Rheumatology Science and Practice. 2021;59(2):119-128 (In Russ.). doi: 10.47360/1995-4484-2021-119-128
36. Choi MY, Costenbader KH. Understanding the concept of preclinical autoimmunity: Prediction and prevention of systemic lupus erythematosus: Identifying risk factors and developing strategies against disease development. Front Immunol. 2022;13:890522. doi: 10.3389/fimmu.2022.890522
37. Aringer M, Alarcón-Riquelme ME, Clowse M, Pons-Estel GJ, Vital EM, Dall’Era M. A glimpse into the future of systemic lupus erythematosus. Ther Adv Musculoskelet Dis. 2022;14:1759720X221086719. doi: 10.1177/1759720X221086719
38. Barturen G, Babaei S, Català-Moll F, Martínez-Bueno M, Makowska Z, Martorell-Marugán J, et al. Integrative analysis reveals a molecular stratification of systemic autoimmune diseases. Arthritis Rheumatol. 2021;73(6):1073-1085. doi: 10.1002/art.41610
39. Sandling JK, Pucholt P, Hultin Rosenberg L, Farias FHG, Kozyrev SV, Eloranta ML, et al. Molecular pathways in patients with systemic lupus erythematosus revealed by gene-centred DNA sequencing. Ann Rheum Dis. 2021;80(1):109-117. doi: 10.1136/annrheumdis-2020-218636
40. Omarjee O, Picard C, Frachette C, Moreews M, Rieux-Laucat F, Soulas-Sprauel P, et al. Monogenic lupus: Dissecting heterogeneity. Autoimmun Rev. 2019;18(10):102361. doi: 10.1016/j.autrev.2019.102361
41. van Vollenhoven RF, Mosca M, Bertsias G, Isenberg D, Kuhn A, Lerstrøm K, et al. Treat-to-target in systemic lupus erythematosus: Recommendations from an international task force. Ann Rheum Dis. 2014;73(6):958-967. doi: 10.1136/annrheumdis-2013-205139
42. Parra Sánchez AR, Voskuyl AE, van Vollenhoven RF. Treat-to-target in systemic lupus erythematosus: Advancing towards its implementation. Nat Rev Rheumatol. 2022;18(3):146-157. doi: 10.1038/s41584-021-00739-3
43. Gatto M, Zen M, Iaccarino L, Doria A. New therapeutic strategies in systemic lupus erythematosus management. Nat Rev Rheumatol. 2019;15(1):30-48. doi: 10.1038/s41584-018-0133-2
44. Dörner T, Furie R. Novel paradigms in systemic lupus erythematosus. Lancet. 2019;393(10188):2344-2358. doi: 10.1016/S0140-6736(19)30546-X
45. Ugarte-Gil MF, Mendoza-Pinto C, Reátegui-Sokolova C, PonsEstel GJ, van Vollenhoven RF, Bertsias G, et al. Achieving remission or low disease activity is associated with better outcomes in patients with systemic lupus erythematosus: A systematic literature review. Lupus Sci Med. 2021;8(1):e000542. doi: 10.1136/lupus2021-000542
46. Soloviev SK, Aseeva EA, Zotkin EG, Kireeva SYu, Nasonov EL. Problems of low activity and remission in systemic lupus erythematosus. Nauchno-Prakticheskaya Revmatologia = Rheumatology Science and Practice. 2019;57(2):218- 221 (In Russ.). doi: 10.14412/1995-4484-2019-218-221
47. Fanouriakis A, Kostopoulou M, Alunno A, Aringer M, Bajema I, Boletis JN, et al. 2019 update of the EULAR recommendations for the management of systemic lupus erythematosus. Ann Rheum Dis. 2019;78(6):736-745. doi: 10.1136/annrheumdis-2019-215089
48. Gordon C, Amissah-Arthur MB, Gayed M, Brown S, Bruce IN, D’Cruz D, et al.; British Society for Rheumatology Standards, Audit and Guidelines Working Group. The British Society for Rheumatology guideline for the management of systemic lupus erythematosus in adults. Rheumatology (Oxford). 2018;57(1):e1- e45. doi: 10.1093/rheumatology/kex286
49. Pons-Estel BA, Bonfa E, Soriano ER, Cardiel MH, Izcovich A, Popoff F, et al.; Grupo Latino Americano de Estudio del Lupus (GLADEL) and Pan-American League of Associations of Rheumatology (PANLAR). First Latin American clinical practice guidelines for the treatment of systemic lupus erythematosus: Latin American Group for the Study of Lupus (GLADEL, Grupo Latino Americano de Estudio del Lupus) Pan-American League of Associations of Rheumatology (PANLAR). Ann Rheum Dis. 2018;77(11):1549-1557. doi: 10.1136/annrheumdis-2018-213512
50. Tektonidou MG, Andreoli L, Limper M, Amoura Z, Cervera R, Costedoat-Chalumeau N, et al. EULAR recommendations for the management of antiphospholipid syndrome in adults. Ann Rheum Dis. 2019;78(10):1296-1304. doi: 10.1136/annrheumdis-2019-215213
51. Fanouriakis A, Kostopoulou M, Cheema K, Anders HJ, Aringer M, Bajema I, et al. 2019 update of the Joint European League against Rheumatism and European Renal Association-European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of lupus nephritis. Ann Rheum Dis. 2020;79(6):713-723. doi: 10.1136/annrheumdis2020-216924
52. Reshetnyak TM, Nurbaeva KS. Direct-acting oral anticoagulants in antiphospholipid syndrome. Nauchno-Prakticheskaya Revmatologia = Rheumatology Science and Practice. 2020;58(6):708-715 (In Russ.). doi: 10.47360/1995-4484-2020-708-715
53. Yavne Y, Edel Y, Berman J, Eviatar T, Shepshelovich D. Quality evaluation of the underlying evidence in the updated treatment recommendations for systemic lupus erythematosus. Rheumatology (Oxford). 2021;61(1):240-248. doi: 10.1093/rheumatology/keab306
54. Solovyev SK, Aseeva EA, Popkova TV, Lila AM, Mazurov VI, Nasonov EL. Systemic lupus erythematosus: New horizons for diagnosis and therapy. Nauchno-Prakticheskaya Revmatologia = Rheumatology Science and Practice. 2020;58(1):5-14 (In Russ.). doi: 10.14412/1995-4484-2020-5-14
55. Kandane-Rathnayake R, Louthrenoo W, Hoi A, Luo SF, Wu YJ, Chen YH, et al.; Asia-Pacific Lupus Collaboration. ‘Not at target’: Prevalence and consequences of inadequate disease control in systemic lupus erythematosus – a multinational observational cohort study. Arthritis Res Ther. 2022;24(1):70. doi: 10.1186/s13075-022-02756-3
56. Bultink IEM, de Vries F, van Vollenhoven RF, Lalmohamed A. Mortality, causes of death and influence of medication use in patients with systemic lupus erythematosus vs matched controls. Rheumatology (Oxford). 2021;60(1):207-216. doi: 10.1093/rheumatology/keaa267
57. Singh RR, Yen EY. SLE mortality remains disproportionately high, despite improvements over the last decade. Lupus. 2018;27(10): 1577-1581. doi: 10.1177/0961203318786436
58. Shin JI, Li H, Park S, Yang JW, Lee KH, Jo Y, et al. Induction and maintenance treatment of lupus nephritis: A comprehensive review of meta-analyses. J Clin Med. 2022;11(2):343. doi: 10.3390/jcm11020343
59. Mok CC. Calcineurin inhibitors in systemic lupus erythematosus. Best Pract Res Clin Rheumatol. 2017;31(3):429-438. doi: 10.1016/j.berh.2017.09.010
60. Dall’Era M. Treatment of lupus nephritis: Current paradigms and emerging strategies. Curr Opin Rheumatol. 2017;29(3):241-247. doi: 10.1097/BOR.0000000000000381
61. Rovin BH, Solomons N, Pendergraft WF 3rd, Dooley MA, Tumlin J, Romero-Diaz J, et al.; AURA-LV Study Group. A randomized, controlled double-blind study comparing the efficacy and safety of dose-ranging voclosporin with placebo in achieving remission in patients with active lupus nephritis. Kidney Int. 2019; 95(1):219-231. doi: 10.1016/j.kint.2018.08.025
62. Rovin BH, Teng YKO, Ginzler EM, Arriens C, Caster DJ, Romero-Diaz J, et al. Efficacy and safety of voclosporin versus placebo for lupus nephritis (AURORA 1): A double-blind, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet. 2021;397(10289):2070-2080. doi: 10.1016/S0140-6736(21)00578-X
63. Arriens C, Polyakova S, Adzerikho I, Randhawa S, Solomons N. OP0277 AURORA phase 3 study demonstrates voclosporin statistical superiority over standard of care in lupus nephritis (LN). Ann Rheum Dis. 2020;79:172.2-172.3. doi: 10.1136/annrheumdis2020-eular.5010
64. Sin FE, Isenberg D. An evaluation of voclosporin for the treatment of lupus nephritis. Expert Opin Pharmacother. 2018;19(14):1613- 1621. doi: 10.1080/14656566.2018.1516751
65. Nasonov EL, Solovyev SK. Prospects for pharmacotherapy of systemic lupus erythematosus. Nauchno-Prakticheskaya Revmatologia = Rheumatology Science and Practice. 2014;52(3):311-321 (In Russ.). doi: 10.14412/1995-4484-2014-311-321
66. Yavuz S, Lipsky PE. Current status of the evaluation and management of lupus patients and future prospects. Front Med (Lausanne). 2021;8:682544. doi: 10.3389/fmed.2021.682544
67. Allen ME, Rus V, Szeto GL. Leveraging heterogeneity in systemic lupus erythematosus for new therapies. Trends Mol Med. 2021; 27(2):152-171. doi: 10.1016/j.molmed.2020.09.009
68. Idborg H, Oke V. Cytokines as biomarkers in systemic lupus erythematosus: Value for diagnosis and drug therapy. Int J Mol Sci. 2021;22(21):11327. doi: 10.3390/ijms222111327
69. Arora S, Rovin BH. Expert perspective: An approach to refractory lupus nephritis. Arthritis Rheumatol. 2022;74(6):915-926. doi: 10.1002/art.42092
70. Zucchi D, Elefante E, Schilirò D, Signorini V, Trentin F, Bortoluzzi A, et al. One year in review 2022: Systemic lupus erythematosus. Clin Exp Rheumatol. 2022;40(1):4-14. doi: 10.55563/clinexprheumatol/nolysy
71. Ruiz-Irastorza G, Bertsias G. Treating systemic lupus erythematosus in the 21st century: New drugs and new perspectives on old drugs. Rheumatology (Oxford). 2020;59(Suppl 5):v69-v81. doi: 10.1093/rheumatology/keaa403
72. Merrill JT, Neuwelt CM, Wallace DJ, Shanahan JC, Latinis KM, Oates JC, et al. Efficacy and safety of rituximab in moderately-to- severely active systemic lupus erythematosus: The randomized, double-blind, phase II/III systemic lupus erythematosus evaluation of rituximab trial. Arthritis Rheum. 2010;62(1):222-233. doi: 10.1002/art.27233
73. Rovin BH, Furie R, Latinis K, Looney RJ, Fervenza FC, Sanchez-Guerrero J, et al.; LUNAR Investigator Group. Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: The Lupus Nephritis Assessment with Rituximab study. Arthritis Rheum. 2012;64(4):1215-1226. doi: 10.1002/art.34359
74. Rydén-Aulin M, Boumpas D, Bultink I, Callejas Rubio JL, Caminal-Montero L, Castro A, et al. Off-label use of rituximab for systemic lupus erythematosus in Europe. Lupus Sci Med. 2016;3(1): e000163. doi: 10.1136/lupus-2016-000163
75. Nasonov EL, Beketova TV, Ananyeva LP, Vasilyev VI, Solovyev SK, Avdeeva AS Prospects for anti-B-cell therapy in immuno-inflammatory rheumatic diseases. Nauchno-Prakticheskaya Revmatologia = Rheumatology Science and Practice. 2019;57:1-40 (In Russ.). doi: 10.14412/1995-4484-2019-3-40
76. Furie RA, Aroca G, Cascino MD, Garg JP, Rovin BH, Alvarez A, et al. B-cell depletion with obinutuzumab for the treatment of proliferative lupus nephritis: A randomised, double-blind, placebocontrolled trial. Ann Rheum Dis. 2022;81(1):100-107. doi: 10.1136/annrheumdis-2021-220920
77. Mysler EF, Spindler AJ, Guzman R, Bijl M, Jayne D, Furie RA, et al. Efficacy and safety of ocrelizumab in active proliferative lupus nephritis: Results from a randomized, double-blind, phase III study. Arthritis Rheum. 2013;65(9):2368-2379. doi: 10.1002/art.38037
78. Clowse ME, Wallace DJ, Furie RA, Petri MA, Pike MC, Leszczyński P, et al.; EMBODY Investigator Group. Efficacy and safety of epratuzumab in moderately to severely active systemic lupus erythematosus: Results from two phase III randomized, double-blind, placebo-controlled trials. Arthritis Rheumatol. 2017;69(2):362-375. doi: 10.1002/art.39856
79. Merrill JT, Wallace DJ, Wax S, Kao A, Fraser PA, Chang P, et al.; ADDRESS II Investigators. Efficacy and safety of atacicept in patients with systemic lupus erythematosus: Results of a twentyfour-week, multicenter, randomized, double-blind, placebo-controlled, parallel-arm, phase IIb study. Arthritis Rheumatol. 2018;70(2):266-276. doi: 10.1002/art.40360
80. Ginzler EM, Wax S, Rajeswaran A, Copt S, Hillson J, Ramos E, et al. Atacicept in combination with MMF and corticosteroids in lupus nephritis: Results of a prematurely terminated trial. Arthritis Res Ther. 2012;14(1):R33. doi: 10.1186/ar3738
81. Merrill JT, van Vollenhoven RF, Buyon JP, Furie RA, Stohl W, Morgan-Cox M, et al. Efficacy and safety of subcutaneous tabalumab, a monoclonal antibody to B-cell activating factor, in patients with systemic lupus erythematosus: results from ILLUMINATE-2, a 52-week, phase III, multicentre, randomised, double-blind, placebo-controlled study. Ann Rheum Dis. 2016; 75(2):332-340. doi: 10.1136/annrheumdis-2015-207654
82. Merrill JT, Shanahan WR, Scheinberg M, Kalunian KC, Wofsy D, Martin RS. Phase III trial results with blisibimod, a selective inhibitor of B-cell activating factor, in subjects with systemic lupus erythematosus (SLE): Results from a randomised, double-blind, placebo-controlled trial. Ann Rheum Dis. 2018;77(6):883-889. doi: 10.1136/annrheumdis-2018-213032
83. US National library of Medicine. ClinicalTrials.gov URL: https://ClinicalTrials.gov/show/NCT02885610)
84. US National library of Medicine. ClinicalTrials.gov URL: https://ClinicalTrials.gov/show/NCT04082416)
85. Furie R, Morand EF, Bruce IN, Manzi S, Kalunian K, Vital EM, et al. Type I interferon inhibitor anifrolumab in active systemic lupus erythematosus (TULIP-1): A randomised, controlled, phase 3 trial. Lancet Rheumatol. 2019;1(4):e208-e219.
86. Morand EF, Furie R, Tanaka Y, Bruce IN, Askanase AD, Richez C, et al.; TULIP-2 Trial Investigators. Trial of anifrolumab in active systemic lupus erythematosus. N Engl J Med. 2020; 382(3):211-221. doi: 10.1056/NEJMoa1912196
87. Chatham WW, Furie R, Saxena A, Brohawn P, Schwetje E, Abreu G, et al. Long-term safety and efficacy of anifrolumab in adults with systemic lupus erythematosus: Results of a phase II open-label extension study. Arthritis Rheumatol. 2021;73(5):816- 825. doi: 10.1002/art.41598
88. Jayne D, Rovin B, Mysler EF, Furie RA, Houssiau FA, Trasieva T, et al. Phase II randomised trial of type I interferon inhibitor anifrolumab in patients with active lupus nephritis. Ann Rheum Dis. 2022;81(4):496-506. doi: 10.1136/annrheumdis-2021-221478
89. Nasonov EL, Avdeeva AS, Popkova TV. New possibilities of pharmacotherapy for systemic lupus erythematosus: Prospects for the use of anifrolumab (monoclonal antibodies to type I interferon receptor). Nauchno-Prakticheskaya Revmatologia = Rheumatology Science and Practice. 2021;59(5):537- 546 (In Russ.). doi: 10.47360/1995-4484-2021-537-546
90. Houssiau FA, Thanou A, Mazur M, Ramiterre E, Gomez Mora DA, Misterska-Skora M, et al. IFN-α kinoid in systemic lupus erythematosus: Results from a phase IIb, randomised, placebo-controlled study. Ann Rheum Dis. 2020;79(3):347-355. doi: 10.1136/annrheumdis-2019-216379
91. Merrill JT, Burgos-Vargas R, Westhovens R, Chalmers A, D’Cruz D, Wallace DJ, et al. The efficacy and safety of abatacept in patients with non-life-threatening manifestations of systemic lupus erythematosus: Results of a twelve-month, multicenter, exploratory, phase IIb, randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 2010;62(10):3077-3087. doi: 10.1002/art.27601
92. Furie R, Nicholls K, Cheng TT, Houssiau F, Burgos-Vargas R, Chen SL, et al. Efficacy and safety of abatacept in lupus nephritis: A twelve-month, randomized, double-blind study. Arthritis Rheumatol. 2014;66(2):379-389. doi: 10.1002/art.38260
93. Pimentel-Quiroz VR, Ugarte-Gil MF, Alarcón GS. Abatacept for the treatment of systemic lupus erythematosus. Expert Opin Investig Drugs. 2016;25(4):493-499. doi: 10.1517/13543784.2016.1154943
94. Furie RA, Bruce IN, Dörner T, Leon MG, Leszczyński P, Urowitz M, et al. Phase 2, randomized, placebo-controlled trial of dapirolizumab pegol in patients with moderate-to-severe active systemic lupus erythematosus. Rheumatology (Oxford). 2021;60(11):5397- 5407. doi: 10.1093/rheumatology/keab381
95. Wallace DJ, Stohl W, Furie RA, Lisse JR, McKay JD, Merrill JT, et al. A phase II, randomized, double-blind, placebo-controlled, dose-ranging study of belimumab in patients with active systemic lupus erythematosus. Arthritis Rheum. 2009;61(9):1168-1178. doi: 10.1002/art.24699
96. Furie R, Petri M, Zamani O, Cervera R, Wallace DJ, Tegzová D, et al.; BLISS-76 Study Group. A phase III, randomized, placebocontrolled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus. Arthritis Rheum. 2011;63(12):3918-3930. doi: 10.1002/art.30613
97. Navarra SV, Guzmán RM, Gallacher AE, Hall S, Levy RA, Jimenez RE, et al.; BLISS-52 Study Group. Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: A randomised, placebo-controlled, phase 3 trial. Lancet. 2011;377(9767):721-731. doi: 10.1016/S0140-6736(10)61354-2
98. Sheikh SZ, Scheinberg MA, Cheng-Chung Wei J, Tegzova D, Stohl W, Acayaba de Toledo R, et al. Mortality and adverse events of special interest with intravenous belimumab for adults with active, autoantibody-positive systemic lupus erythematosus (BASE): A multicentre, double-blind, randomised, placebo-controlled, phase 4 trial. Lancet Rheumatol. 2021:e122-e130. doi: 10.1016/S2665-9913(20)30355-6
99. Manzi S, Sánchez-Guerrero J, Merrill JT, Furie R, Gladman D, Navarra SV, et al.; BLISS-52 and BLISS-76 Study Groups. Effects of belimumab, a B lymphocyte stimulator-specific inhibitor, on disease activity across multiple organ domains in patients with systemic lupus erythematosus: Combined results from two phase III trials. Ann Rheum Dis. 2012;71(11):1833-1838. doi: 10.1136/annrheumdis-2011-200831
100. Furie R, Rovin BH, Houssiau F, Malvar A, Teng YKO, Contreras G, et al. Two-year, randomized, controlled trial of belimumab in lupus nephritis. N Engl J Med. 2020;383(12):1117-1128. doi: 10.1056/NEJMoa2001180
101. Rovin BH, Furie R, Teng YKO, Contreras G, Malvar A, Yu X, et al. A secondary analysis of the Belimumab International Study in Lupus Nephritis trial examined effects of belimumab on kidney outcomes and preservation of kidney function in patients with lupus nephritis. Kidney Int. 2022;101(2):403-413. doi: 10.1016/j.kint.2021.08.027
102. Shrestha S, Budhathoki P, Adhikari Y, Marasini A, Bhandari S, Mir WAY, et al. Belimumab in lupus nephritis: A systematic review and meta-analysis. Cureus. 2021;13(12):e20440. doi: 10.7759/cureus.20440
103. Plüß M, Piantoni S, Tampe B, Kim AHJ, Korsten P. Belimumab for systemic lupus erythematosus – Focus on lupus nephritis. Hum Vaccin Immunother. 2022:2072143. doi: 10.1080/21645515.20 22.2072143
104. Rovin BH, van Vollenhoven RF, Aranow C, Wagner C, Gordon R, Zhuang Y, et al. A multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of treatment with sirukumab (CNTO 136) in patients with active lupus nephritis. Arthritis Rheumatol. 2016;68(9):2174-2183. doi: 10.1002/art.39722
105. Illei GG, Shirota Y, Yarboro CH, Daruwalla J, Tackey E, Takada K, et al. Tocilizumab in systemic lupus erythematosus: Data on safety, preliminary efficacy, and impact on circulating plasma cells from an open-label phase I dosage-escalation study. Arthritis Rheum. 2010;62(2):542-552. doi: 10.1002/art.27221
106. Wallace DJ, Strand V, Merrill JT, Popa S, Spindler AJ, Eimon A, et al. Efficacy and safety of an interleukin 6 monoclonal antibody for the treatment of systemic lupus erythematosus: A phase II dose-ranging randomised controlled trial. Ann Rheum Dis. 2017;76(3):534-542. doi: 10.1136/annrheumdis-2016-209668
107. van Vollenhoven RF, Hahn BH, Tsokos GC, Wagner CL, Lipsky P, Touma Z, et al. Efficacy and safety of ustekinumab, an IL-12 and IL-23 inhibitor, in patients with active systemic lupus erythematosus: Results of a multicentre, double-blind, phase 2, randomised, controlled study. Lancet. 2018;392(10155): 1330-1339. doi: 10.1016/S0140-6736(18)32167-6
108. van Vollenhoven RF, Hahn BH, Tsokos GC, Lipsky P, Fei K, Gordon RM, et al. Maintenance of efficacy and safety of ustekinumab through one year in a phase II multicenter, prospective, randomized, double-blind, placebo-controlled crossover trial of patients with active systemic lupus erythematosus. Arthritis Rheumatol. 2020;72(5):761-768. doi: 10.1002/art.41179
109. van Vollenhoven RF, Kalunian KC, Dörner T, et alPhase 3, multicentre, randomised, placebo-controlled study evaluating the efficacy and safety of ustekinumab in patients with systemic lupus erythematosus. Ann Rheum Dis. Published Online First: 07 July 2022. doi: 10.1136/ard-2022-222858
110. US National library of Medicine. ClinicalTrials.gov. URL: https://ClinicalTrials.gov/show/NCT04181762.
111. US National library of Medicine. ClinicalTrials.gov. URL: https://ClinicalTrials.gov/show/NCT04376827.
112. Boedigheimer MJ, Martin DA, Amoura Z, Sánchez-Guerrero J, Romero-Diaz J, Kivitz A, et al. Safety, pharmacokinetics and pharmacodynamics of AMG 811, an anti-interferon-γ monoclonal antibody, in SLE subjects without or with lupus nephritis. Lupus Sci Med. 2017;4(1):e000226. doi: 10.1136/lupus-2017-000226
113. Werth VP, Fiorentino D, Sullivan BA, Boedigheimer MJ, Chiu K, Wang C, et al. Brief report: Pharmacodynamics, safety, and clinical efficacy of AMG 811, a human anti-interferon-γ antibody, in patients with discoid lupus erythematosus. Arthritis Rheumatol. 2017;69(5):1028-1034. doi: 10.1002/art.40052
114. US National library of Medicine. ClinicalTrials.gov. URL: https://ClinicalTrials.gov/show/NCT02847598
115. US National library of Medicine. ClinicalTrials.gov. URL: https://ClinicalTrials.gov/show/NCT04895241.
116. Werth V, Furie R, Romero-Díaz J, Navarra S, Kalunian K, van Vollenhoven R, et al. BIIB059. A humanized monoclonal antibody targeting blood dendritic cell antigen 2 on plasmacytoid dendritic cells, shows dose-related efficacy in a phase 2 study in participants with active cutaneous lupus erythematosus. Arthritis Rheumatol. 2020;72(Suppl 10). URL: https://acrabstracts.org/abstract/biib059-a-humanized-monoclonal-antibody-targetingblood-dendritic-cell-antigen-2-on-plasmacytoid-dendritic-cellsshows-dose-related-efficacy-in-a-phase-2-study-in-participantswith-active-cutaneous (Accessed: 11th July 2022).
117. Furie R, Werth VP, Merola JF, Stevenson L, Reynolds TL, Naik H, et al. Monoclonal antibody targeting BDCA2 ameliorates skin lesions in systemic lupus erythematosus. J Clin Invest. 2019; 129(3):1359-1371. doi: 10.1172/JCI124466
118. Zhang H, Liu Z, Huang L, Hou J, Zhou M, Huang X, et al. The short-term efficacy of bortezomib combined with glucocorticoids for the treatment of refractory lupus nephritis. Lupus. 2017;26(9):952-958. doi: 10.1177/0961203316686703
119. Segarra A, Arredondo KV, Jaramillo J, Jatem E, Salcedo MT, Agraz I, et al. Efficacy and safety of bortezomib in refractory lupus nephritis: A single-center experience. Lupus. 2020;29(2): 118-125. doi: 10.1177/0961203319896018
120. Ostendorf L, Burns M, Durek P, Heinz GA, Heinrich F, Garantziotis P, et al. Targeting CD38 with daratumumab in refractory systemic lupus erythematosus. N Engl J Med. 2020;383(12):1149-1155. doi: 10.1056/NEJMoa2023325
121. Hasni S, Gupta S, Davis M, Poncio E, Temesgen-Oyelakin Y, Joyal E, et al. Safety and tolerability of omalizumab: A randomized clinical trial of humanized anti-IgE monoclonal antibody in systemic lupus erythematosus. Arthritis Rheumatol. 2019;71(7): 1135-1140. doi: 10.1002/art.40828
122. US National library of Medicine. ClinicalTrials.gov. URL: https://ClinicalTrials.gov/show/NCT03843125.
123. US National library of Medicine. ClinicalTrials.gov. URL: https://ClinicalTrials.gov/show/NCT03616964.
124. US National library of Medicine. ClinicalTrials.gov. URL https://ClinicalTrials.gov/show/NCT03616912.
125. Wallace DJ, Furie RA, Tanaka Y, Kalunian KC, Mosca M, Petri MA, et al. Baricitinib for systemic lupus erythematosus: A double-blind, randomised, placebo-controlled, phase 2 trial. Lancet. 2018;392(10143):222-231. doi: 10.1016/S0140-6736(18) 31363-1
126. Hasni SA, Gupta S, Davis M, Poncio E, Temesgen-Oyelakin Y, Carlucci PM, et al. Phase 1 double-blind randomized safety trial of the Janus kinase inhibitor tofacitinib in systemic lupus erythematosus. Nat Commun. 2021;12(1):3391. doi: 10.1038/s41467-021- 23361-z
127. Morand E, Pike M, Merrill JT, van Vollenhoven R, Werth VP, Hobar C, et al. LB0004 Efficacy and safety of deucravacitinib, an oral, selective, allosteric Tyk2 inhibitor, in patients with active systemic lupus erythematosus: A phase 2, Randomized, DoubleBlind, Placebo-Controlled Study. Ann Rheum Dis. 2022;81:209. doi: 10.1136/annrheumdis-2022-eular.5020a
128. Isenberg D, Furie R, Jones NS, Guibord P, Galanter J, Lee C, et al. Efficacy, safety, and pharmacodynamic effects of the Bruton’s tyrosine kinase inhibitor fenebrutinib (GDC-0853) in systemic lupus erythematosus: Results of a phase II, randomized, double-blind, placebo-controlled trial. Arthritis Rheumatol. 2021; 73(10):1835-1846. doi: 10.1002/art.41811
129. US National library of Medicine. ClinicalTrials.gov. URL: https://ClinicalTrials.gov/show/NCT03021499.
130. Furie RA, Hough DR, Gaudy A, Ye Y, Korish S, Delev N, et al. Iberdomide in patients with systemic lupus erythematosus: A randomised, double-blind, placebo-controlled, ascending-dose, phase 2a study. Lupus Sci Med. 2022;9(1):e000581. doi: 10.1136/lupus-2021-000581
131. Burge DJ, Eisenman J, Byrnes-Blake K, Smolak P, Lau K, Cohen SB, et al. Safety, pharmacokinetics, and pharmacodynamics of RSLV-132, an RNase-Fc fusion protein in systemic lupus erythematosus: A randomized, double-blind, placebo-controlled study. Lupus. 2017;26(8):825-834. doi: 10.1177/0961203316678675
132. Burge D, Doedens J, Eisenman J, Elkon K, Gabel C, Posada J. THU0293 Safety, pharmacokinetics, enzyme activity, and immunogenicity of RSLV-132, a novel RNAse fusion protein developed to reduce RNA-containing immune complexes in systemic lupus erythematosus. Ann Rheum Dis. 2016;75:292-293. doi: 10.1136/ annrheumdis-2016-eular.2744
133. Szelinski F, Lino AC, Dörner T. B cells in systemic lupus erythematosus. Curr Opin Rheumatol. 2022;34(2):125-132. doi: 10.1097/BOR.0000000000000865
134. Piantoni S, Korsten P. Rituximab-a B cell targeted therapy in systemic lupus erythematosus: Where do we stand? Rheumatology (Oxford). 2022;61(5):1752-1755. doi: 10.1093/rheumatology/keac095
135. Lee DSW, Rojas OL, Gommerman JL. B cell depletion therapies in autoimmune disease: Advances and mechanistic insights. Nat Rev Drug Discov. 2021;20(3):179-199. doi: 10.1038/s41573-020- 00092-2
136. Atisha-Fregoso Y, Toz B, Diamond B. Meant to B: B cells as a therapeutic target in systemic lupus erythematosus. J Clin Invest. 2021;131(12):e149095. doi: 10.1172/JCI149095
137. Fernández González R, Abida R, Gisca E, Duarte L, Isenberg DA. Can we predict if patients with SLE will require more than one cycle of rituximab? Rheumatology (Oxford). 2022;61(5):1892-1899. doi: 10.1093/rheumatology/keab527
138. Gomez Mendez LM, Cascino MD, Garg J, Katsumoto TR, Brakeman P, Dall’Era M, et al. Peripheral blood B cell depletion after rituximab and complete response in lupus nephritis. Clin J Am Soc Nephrol. 2018;13(10):1502-1509. doi: 10.2215/CJN.01070118
139. Marinov AD, Wang H, Bastacky SI, van Puijenbroek E, Schindler T, Speziale D, et al. The type II anti-CD20 antibody obinutuzumab (GA101) is more effective than rituximab at depleting B cells and treating disease in a murine lupus model. Arthritis Rheumatol. 2021;73(5):826-836. doi: 10.1002/art.41608
140. Stohl W, Hilbert DM. The discovery and development of belimumab: The anti-BLyS-lupus connection. Nat Biotechnol. 2012;30(1):69-77. doi: 10.1038/nbt.2076
141. Nasonov EL, Reshetnyak TM, Denisov LN, Stanislav ML, Solovyov SK. Belimumab: Advances in drug therapy for systemic lupus erythematosus. Nauchno-Prakticheskaya Revmatologia = Rheumatology Science and Practice. 2012;50(5):13-19 (In Russ.). doi: 10.14412/1995-4484-2012-1174
142. Nasonov EL, Popkova TV, Lila AM. Belimumab in the treatment of systemic lupus erythematosus: 20 years of basic research, 10 years of clinical practice. Nauchno-Prakticheskaya Revmatologia = Rheumatology Science and Practice. 2021;59(4):367-383 (In Russ.). doi: 10.47360/1995-4484-2021-367-383
143. Smulski CR, Eibel H. BAFF and BAFF-Receptor in B cell selection and survival. Front Immunol. 2018;9:2285. doi: 10.3389/fimmu.2018.02285
144. Vincent FB, Morand EF, Schneider P, Mackay F. The BAFF/ APRIL system in SLE pathogenesis. Nat Rev Rheumatol. 2014;10(6):365-373. doi: 10.1038/nrrheum.2014.33
145. Singh JA, Shah NP, Mudano AS. Belimumab for systemic lupus erythematosus. Cochrane Database Syst Rev. 2021;2(2):CD010668. doi: 10.1002/14651858.CD010668.pub2
146. Poh YJ, Baptista B, D’Cruz DP. Subcutaneous and intravenous belimumab in the treatment of systemic lupus erythematosus: A review of data on subcutaneous and intravenous administration. Expert Rev Clin Immunol. 2017;13(10):925-938. doi: 10.1080/1744 666X.2017.1371592
147. Wise LM, Stohl W. Belimumab and rituximab in systemic lupus erythematosus: A tale of two B cell-targeting agents. Front Med (Lausanne). 2020;7:303. doi: 10.3389/fmed.2020.00303
148. Bela MM, Espinosa G, Cervera R. Next stop in the treatment of refractory systemic lupus erythematosus: B-cell targeted combined therapy. Lupus. 2021;30(1):134-140. doi: 10.1177/0961203320965707
149. Shipa M, Embleton-Thirsk A, Parvaz M, Santos LR, Muller P, Chowdhury K, et al.; BEAT-LUPUS Investigators. Effectiveness of belimumab after rituximab in systemic lupus erythematosus: A randomized controlled trial. Ann Intern Med. 2021;174(12):1647- 1657. doi: 10.7326/M21-2078
150. Aranow C, Allaart C, Amoura Z, Bruce I, Cagnoli P, Furie R, et al. Efficacy and safety of subcutaneous belimumab (BEL) and rituximab (RTX) sequential therapy in patients with systemic lupus erythematosus: The phase 3, randomized, placebo-controlled BLISS-BELIEVE Study. Arthritis Rheumatol. 2021;73(Suppl 10).
151. Hiepe F, Dörner T, Hauser AE, Hoyer BF, Mei H, Radbruch A. Long-lived autoreactive plasma cells drive persistent autoimmune inflammation. Nat Rev Rheumatol. 2011;7(3):170-178. doi: 10.1038/nrrheum.2011.1
152. Lokhorst HM, Plesner T, Laubach JP, Nahi H, Gimsing P, Hansson M, et al. Targeting CD38 with daratumumab monotherapy in multiple myeloma. N Engl J Med. 2015;373(13):1207-1219. doi: 10.1056/NEJMoa1506348
153. Orvain C, Boulch M, Bousso P, Allanore Y, Avouac J. Is there a place for chimeric antigen receptor-T cells in the treatment of chronic autoimmune rheumatic diseases? Arthritis Rheumatol. 2021;73(11):1954-1965. doi: 10.1002/art.41812
154. Kansal R, Richardson N, Neeli I, Khawaja S, Chamberlain D, Ghani M, et al. Sustained B cell depletion by CD19-targeted CAR T cells is a highly effective treatment for murine lupus. Sci Transl Med. 2019;11(482):eaav1648. doi: 10.1126/scitranslmed. aav1648
155. Jin X, Xu Q, Pu C, Zhu K, Lu C, Jiang Y, et al. Therapeutic efficacy of anti-CD19 CAR-T cells in a mouse model of systemic lupus erythematosus. Cell Mol Immunol. 2021;18(8):1896-1903. doi: 10.1038/s41423-020-0472-1
156. Mougiakakos D, Krönke G, Völkl S, Kretschmann S, Aigner M, Kharboutli S, et al. CD19-targeted CAR T cells in refractory systemic lupus erythematosus. N Engl J Med. 2021;385(6):567-569. doi: 10.1056/NEJMc2107725
157. Crow MK, Olferiev M, Kirou KA. Type I interferons in autoimmune disease. Annu Rev Pathol. 2019;14:369-393. doi: 10.1146/ annurev-pathol-020117-043952
158. Nasonov EL, Avdeeva AS. Immunoinflammatory rheumatic diseases associated with type I interferon: New evidence. Nauchno-Prakticheskaya Revmatologia = Rheumatology Science and Practice. 2019;57(4):452-461 (In Russ.). doi: 10.14412/1995-4484-2019-452-461
159. Rönnblom L, Leonard D. Interferon pathway in SLE: One key to unlocking the mystery of the disease. Lupus Sci Med. 2019;6(1):e000270. doi: 10.1136/lupus-2018-000270
160. Paredes JL, Niewold TB. Type I interferon antagonists in clinical development for lupus. Expert Opin Investig Drugs. 2020;29(9):1025-1041. doi: 10.1080/13543784.2020.1797677
161. Chaichian Y, Strand V. Interferon-directed therapies for the treatment of systemic lupus erythematosus: A critical update. Clin Rheumatol. 2021;40(8):3027-3037. doi: 10.1007/s10067-020-05526-1
162. Goulden B, Isenberg D. Anti-IFNαR MAbs for the treatment of systemic lupus erythematosus. Expert Opin Biol Ther. 2021; 21(4):519-528. doi: 10.1080/14712598.2021.1841164
163. Peng L, Oganesyan V, Wu H, Dall’Acqua WF, Damschroder MM. Molecular basis for antagonistic activity of anifrolumab, an anti- interferon-α receptor 1 antibody. MAbs. 2015;7(2):428-439. doi: 10.1080/19420862.2015.1007810
164. Riggs JM, Hanna RN, Rajan B, Zerrouki K, Karnell JL, Sagar D, et al. Characterisation of anifrolumab, a fully human anti-interferon receptor antagonist antibody for the treatment of systemic lupus erythematosus. Lupus Sci Med. 2018;5(1):e000261. doi: 10.1136/lupus-2018-000261
165. Psarras A, Emery P, Vital EM. Type I interferon-mediated autoimmune diseases: Pathogenesis, diagnosis and targeted therapy. Rheumatology (Oxford). 2017;56(10):1662-1675. doi: 10.1093/rheumatology/kew431
166. Schwartz DM, Kanno Y, Villarino A, Ward M, Gadina M, O’Shea JJ. JAK inhibition as a therapeutic strategy for immune and inflammatory diseases. Nat Rev Drug Discov. 2017;16(12): 843-862. doi: 10.1038/nrd.2017.201
167. Nasonov EL, Lila AM. Janus kinase inhibitors in immuno-inflammatory rheumatic diseases: New opportunities and prospects Nauchno-Prakticheskaya Revmatologia = Rheumatology Science and Practice. 2019;57(1):8-16 (In Russ.). doi: 10.14412/1995-4484-2019-8-16
168. Mok CC. The Jakinibs in systemic lupus erythematosus: progress and prospects. Expert Opin Investig Drugs. 2019;28(1):85-92. doi: 10.1080/13543784.2019.1551358
169. Tanaka Y, Luo Y, O’Shea JJ, Nakayamada S. Janus kinase-targeting therapies in rheumatology: A mechanisms-based approach. Nat Rev Rheumatol. 2022;18(3):133-145. doi:10.1038/s41584-021-00726-8
170. Sanchez GAM, Reinhardt A, Ramsey S, Wittkowski H, Hashkes PJ, Berkun Y, et al. JAK1/2 inhibition with baricitinib in the treatment of autoinflammatory interferonopathies. J Clin Invest. 2018;128(7):3041-3052. doi: 10.1172/JCI98814
171. König N, Fiehn C, Wolf C, Schuster M, Cura Costa E, Tüngler V, et al. Familial chilblain lupus due to a gain-of-function mutation in STING. Ann Rheum Dis. 2017;76(2):468-472. doi: 10.1136/annrheumdis-2016-209841
172. Rodero MP, Frémond ML, Rice GI, Neven B, Crow YJ. JAK inhibition in STING-associated interferonopathy. Ann Rheum Dis. 2016;75(12):e75. doi: 10.1136/annrheumdis-2016-210504
173. You H, Zhang G, Wang Q, Zhang S, Zhao J, Tian X, et al. Successful treatment of arthritis and rash with tofacitinib in systemic lupus erythematosus: The experience from a single centre. Ann Rheum Dis. 2019;78(10):1441-1443. doi: 10.1136/annrheumdis-2019-215455
174. Bisoendial R, Lubberts E. A mechanistic insight into the pathogenic role of interleukin 17A in systemic autoimmune diseases. Mediators Inflamm. 2022;2022:6600264. doi: 10.1155/2022/6600264
175. Klatzmann D, Abbas AK. The promise of low-dose interleukin-2 therapy for autoimmune and inflammatory diseases. Nat Rev Immunol. 2015;15(5):283-294. doi: 10.1038/nri3823
176. He J, Zhang X, Wei Y, Sun X, Chen Y, Deng J, et al. Low-dose interleukin-2 treatment selectively modulates CD4(+) T cell subsets in patients with systemic lupus erythematosus. Nat Med. 2016;22(9):991-993. doi: 10.1038/nm.4148
177. von Spee-Mayer C, Siegert E, Abdirama D, Rose A, Klaus A, Alexander T, et al. Low-dose interleukin-2 selectively corrects regulatory T cell defects in patients with systemic lupus erythematosus. Ann Rheum Dis. 2016;75(7):1407-1415. doi: 10.1136/annrheumdis-2015-207776
178. Humrich JY, von Spee-Mayer C, Siegert E Bertolo M, Rose A, Abdirama D, et al. Low-dose interleukin-2 therapy in refractory systemic lupus erythematosus: An investigator-initiated, single-centre phase 1 and 2a clinical trial. Lancet Rheumatol. 2019;1:e44-e54.
179. Rosenzwajg M, Lorenzon R, Cacoub P, Pham HP, Pitoiset F, El Soufi K, et al. Immunological and clinical effects of low-dose interleukin-2 across 11 autoimmune diseases in a single, open clinical trial. Ann Rheum Dis. 2019;78(2):209-217. doi: 10.1136/annrheumdis-2018-214229
180. He J, Zhang R, Shao M, Zhao X, Miao M, Chen J, et al. Efficacy and safety of low-dose IL-2 in the treatment of systemic lupus erythematosus: A randomised, double-blind, placebo-controlled trial. Ann Rheum Dis. 2020;79(1):141-149. doi: 10.1136/ annrheumdis-2019-215396
181. Huang X, Chen W, Ren G, Zhao L, Guo J, Gong D, et al. Autologous hematopoietic stem cell transplantation for refractory lupus nephritis. Clin J Am Soc Nephrol. 2019;14(5):719-727. doi: 10.2215/CJN.10570918 184. Li W, Chen W, Sun L. An update for mesenchymal stem cell therapy in lupus nephritis. Kidney Dis (Basel). 2021;7(2):79-89. doi: 10.1159/000513741
182. Alexander T, Thiel A, Rosen O, Massenkeil G, Sattler A, Kohler S, et al. Depletion of autoreactive immunologic memory followed by autologous hematopoietic stem cell transplantation in patients with refractory SLE induces long-term remission through de novo generation of a juvenile and tolerant immune system. Blood. 2009;113(1):214-223. doi: 10.1182/blood-2008-07-168286
183. Leng XM, Jiang Y, Zhou DB, Tian XP, Li TS, Wang SJ, et al. Good outcome of severe lupus patients with high-dose immunosuppressive therapy and autologous peripheral blood stem cell transplantation: A 10-year follow-up study. Clin Exp Rheumatol. 2017;35(3):494-499.
184. Cao C, Wang M, Sun J, Peng X, Liu Q, Huang L, et al. Autologous peripheral blood haematopoietic stem cell transplantation for systemic lupus erythematosus: the observation of long-term outcomes in a Chinese centre. Clin Exp Rheumatol. 2017;35(3):500-507.
185. de Silva NL, Seneviratne SL. Haemopoietic stem cell transplantation in Systemic lupus erythematosus: А systematic review. Allergy Asthma Clin Immunol. 2019;15:59. doi: 10.1186/ s13223-019-0373-y
186. Ding DC, Shyu WC, Lin SZ. Mesenchymal stem cells. Cell Transplant. 2011;20(1):5-14. doi: 10.3727/096368910X
187. Li J, Luo M, Li B, Lou Y, Zhu Y, Bai X, et al. Immunomodulatory activity of mesenchymal stem cells in lupus nephritis: Advances and applications. Front Immunol. 2022;13:843192. doi: 10.3389/ fimmu.2022.843192
188. Zeng L, Yu G, Yang K, Xiang W, Li J, Chen H. Efficacy and safety of mesenchymal stem cell transplantation in the treatment of autoimmune diseases (rheumatoid arthritis, systemic lupus erythematosus, inflammatory bowel disease, multiple sclerosis, and ankylosing spondylitis): A systematic review and meta-analysis of randomized controlled trial. Stem Cells Int. 2022;2022:9463314. doi: 10.1155/2022/9463314
189. Deng D, Zhang P, Guo Y, Lim TO. A randomised double-blind, placebo-controlled trial of allogeneic umbilical cord-derived mesenchymal stem cell for lupus nephritis. Ann Rheum Dis. 2017;76(8):1436-1439. doi: 10.1136/annrheumdis-2017-211073
190. Weinstein A, Alexander RV, Zack DJ. A review of complement activation in SLE. Curr Rheumatol Rep. 2021;23(3):16. doi: 10.1007/s11926-021-00984-1
191. Nasonov EL, Reshetnyak TM, Alekberova ZS. Thrombotic microangiopathy in rheumatology: A link between thrombosis and autoimmunity. Terapevticheskii arkhiv. 2020;92(5) (In Russ.). doi: 10.26442/00403660.2020.05.000697
192. Wright RD, Bannerman F, Beresford MW, Oni L. A systematic review of the role of eculizumab in systemic lupus erythematosusassociated thrombotic microangiopathy. BMC Nephrol. 2020;21(1):245. doi: 10.1186/s12882-020-01888-5
193. Pickering MC, Ismajli M, Condon MB, McKenna N, Hall AE, Lightstone L, et al. Eculizumab as rescue therapy in severe resistant lupus nephritis. Rheumatology (Oxford). 2015;54(12):2286- 2288. doi: 10.1093/rheumatology/kev307
194. Spihlman AP, Gadi N, Wu SC, Moulton VR. COVID-19 and systemic lupus erythematosus: Focus on immune response and therapeutics. Front Immunol. 2020;11:589474. doi: 10.3389/fimmu.2020.589474
195. Nasonov EL, Avdeeva AS. B cell depletion in immune-mediated rheumatic diseases and coronavirus disease 2019 (COVID-19). Nauchno-Prakticheskaya Revmatologia = Rheumatology Science and Practice. 2021;59(4):384-393 (In Russ.). doi: 10.47360/1995-4484- 2021-384-393
196. Nasonov EL. Coronavirus disease 2019 (COVID-19) and autoimmunity. Nauchno-Prakticheskaya Revmatologia = Rheumatology Science and Practice. 2021;59(1): 5-30 (In Russ.). doi: 10.47360/1995-4484-2021-5-30
197. Lopez-Leon S, Wegman-Ostrosky T, Perelman C, Sepulveda R, Rebolledo PA, Cuapio A, et al. More than 50 long-term effects of COVID-19: A systematic review and meta-analysis. Sci Rep. 2021;11(1):16144. doi: 10.1038/s41598-021-95565-8
198. Chang SE, Feng A, Meng W, Apostolidis SA, Mack E, Artandi M, et al. New-onset IgG autoantibodies in hospitalized patients with COVID-19. Nat Commun. 2021;12(1):5417. doi: 10.1038/s41467-021-25509-3
199. Tamariz L, Bast E, Abad M, Klimas N, Caralis P, Palacio A. Post COVID-19 joint pain: Preliminary report of the relationship with antinuclear antibodies and inflammation. J Med Virol. 2022;94(8):3479-3481. doi: 10.1002/jmv.27753
200. Cohen H, Cuadrado MJ, Erkan D, Duarte-Garcia A, Isenberg DA, Knight JS, et al. 16th International Congress on Antiphospholipid Antibodies task force report on antiphospholipid syndrome treatment trends. Lupus. 2020;29(12):1571-1593. doi: 10.1177/0961203320950461
201. Erkan D. Expert perspective: Management of microvascular and catastrophic antiphospholipid syndrome. Arthritis Rheumatol. 2021;73(10):1780-1790. doi: 10.1002/art.41891
202. Gao Y, Wang Y, Li R, Zhou X. Comprehensive analysis of clinical trials registration for lupus nephritis therapy on ClinicalTrials.gov. Front Med (Lausanne). 2021;8:680302. doi: 10.3389/fmed.2021. 680302
Review
For citations:
Nasonov E.L., Soloviev S.K., Arshinov A.V. Systemic lupus erythematosus: history and modernity. Rheumatology Science and Practice. 2022;60(4):397-412. (In Russ.) https://doi.org/10.47360/1995-4484-2022-397-412
Views:
1392
Email this article 